Alterations in Circulating Fatty Acid Are Associated With Gut Microbiota Dysbiosis and Inflammation in Multiple Sclerosis

被引:124
|
作者
Saresella, Marina [1 ]
Marventano, Ivana [1 ]
Barone, Monica [2 ]
La Rosa, Francesca [1 ]
Piancone, Federica [1 ]
Mendozzi, Laura [1 ]
d'Arma, Alessia [1 ]
Rossi, Valentina [1 ]
Pugnetti, Luigi [1 ]
Roda, Gabriella [3 ]
Casagni, Eleonora [3 ]
Dei Cas, Michele [4 ]
Paroni, Rita [4 ]
Brigidi, Patrizia [2 ]
Turroni, Silvia [2 ]
Clerici, Mario [1 ,5 ]
机构
[1] IRCCS, Fdn Don Carlo Gnocchi, Milan, Italy
[2] Univ Bologna, Dept Pharm & Biotechnol, Microbial Ecol Hlth Unit, Bologna, Italy
[3] Univ Milan, Dept Pharmaceut Sci, Milan, Italy
[4] Univ Milan, Hlth Sci, Milan, Italy
[5] Univ Milan, Pathophysiol & Trasplantat, Milan, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷
关键词
short-chain fatty acids (SCFAs); butyric acid; caproic acid; gut microbiota; dysbiosis; cytokines; T lymphocytes; multiple sclerosis; MULTIVARIATE-ANALYSIS; T-CELLS; CHAIN; BUTYRATE; BACTERIA; PROPIONATE; METABOLISM; ABSORPTION; MECHANISMS; RECEPTORS;
D O I
10.3389/fimmu.2020.01390
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background:Butyric acid (BA) is a short-chain fatty acid (SCFA) with anti-inflammatory properties, which promotes intestinal barrier function. Medium-chain fatty acids (MCFA), including caproic acid (CA), promote TH1 and TH17 differentiation, thus supporting inflammation. Aim:Since most SCFAs are absorbed in the cecum and colon, the measurement of BA in peripheral blood could provide information on the health status of the intestinal ecosystem. Additionally, given the different immunomodulatory properties of BA and CA the evaluation of their serum concentration, as well as their ratio could be as a simple and rapid biomarker of disease activity and/or treatment efficacy in MS. Methods:We evaluated serum BA and CA concentrations, immune parameters, intestinal barrier integrity and the gut microbiota composition in patients with multiple sclerosis (MS) comparing result to those obtained in healthy controls. Results:In MS, the concentration of BA was reduced and that of CA was increased. Concurrently, the microbiota was depleted of BA producers while it was enriched in mucin-degrading, pro-inflammatory components. The reduced serum concentration of BA seen in MS patients correlated with alterations of the barrier permeability, as evidenced by the higher plasma concentrations of lipopolysaccharide and intestinal fatty acid-binding protein, and inflammation. Specifically, CA was positively associated with CD4+/IFN gamma+ T lymphocytes, and the BA/CA ratio correlated positively with CD4+/CD25(high)/Foxp3+ and negatively with CD4+/IFN gamma+ T lymphocytes. Conclusion:The gut microbiota dysbiosis found in MS is possibly associated with alterations of the SCFA/MCFA ratio and of the intestinal barrier; this could explain the chronic inflammation that characterizes this disease. SCFA and MCFA quantification could be a simple biomarker to evaluate the efficacy of therapeutic and rehabilitation procedures in MS.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Gut microbiota dysbiosis in patients with Multiple Sclerosis
    Mangalam, Ashutosh K.
    Chia, Nicholas
    Chen, Jun
    Kalari, Krishna R.
    Yao, Janet Z.
    Novotna, Martina
    Soldan, Mateo Paz
    Luckey, David
    Marietta, Eric V.
    Jeraldo, Patricio R.
    Chen, Xianfeng
    Weinshenker, Brian G.
    Rodriguez, Moses
    Kantarci, Orhun H.
    Kantarci, Orhun H.
    Nelson, Heidi
    Murray, Joseph A.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [2] The Role of Gut Dysbiosis and Potential Approaches to Target the Gut Microbiota in Multiple Sclerosis
    Ladakis, Dimitrios C. C.
    Bhargava, Pavan
    CNS DRUGS, 2023, 37 (02) : 117 - 132
  • [3] The Role of Gut Dysbiosis and Potential Approaches to Target the Gut Microbiota in Multiple Sclerosis
    Dimitrios C. Ladakis
    Pavan Bhargava
    CNS Drugs, 2023, 37 : 117 - 132
  • [4] Gut Microbiota Dysbiosis, Oxidative Stress, Inflammation, and Epigenetic Alterations in Metabolic Diseases
    Abdolmaleky, Hamid Mostafavi
    Zhou, Jin-Rong
    ANTIOXIDANTS, 2024, 13 (08)
  • [5] Gut dysbiosis and multiple sclerosis
    Noto, Daisuke
    Miyake, Sachiko
    CLINICAL IMMUNOLOGY, 2022, 235
  • [6] Relationship Between Multiple Sclerosis, Gut Dysbiosis, and Inflammation: Considerations for Treatment
    Jank, Larissa
    Bhargava, Pavan
    NEUROLOGIC CLINICS, 2024, 42 (01) : 55 - 76
  • [7] Dysbiosis and Gut Microbiota Modulation in Systemic Sclerosis
    Calil Lemos, Maria Paula
    Zucoloto, Talita Graminha
    Oliveira, Maria Carolina
    Vilela de Oliveira, Gislane Lelis
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2022, 28 (02) : E568 - E573
  • [8] Gut microbiota alterations and nutritional intervention in multiple sclerosis disease
    Noguera-Navarro, Clara
    Navas-Carrillo, Diana
    Orenes-Pinero, Esteban
    FOOD REVIEWS INTERNATIONAL, 2023, 39 (08) : 5279 - 5296
  • [9] The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study
    Paraschiv, Andreea-Cristina
    Vacaras, Vitalie
    Nistor, Cristina
    Vacaras, Cristiana
    Strilciuc, Stefan
    Muresanu, Dafin F.
    MICROBIAL CELL, 2024, 11 (01): : 106 - 115
  • [10] Dysbiosis of Gut Fungal Microbiota is Associated With Mucosal Inflammation in Crohn's Disease
    Li, Qiurong
    Wang, Chenyang
    Tang, Chun
    Ms, Qin He
    Li, Ning
    Li, Jieshou
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2014, 48 (06) : 513 - 523